Booster vaccination after neonatal priming with acellular pertussis vaccine

Markus Knuf; Heinz-Josef Schmitt; Jeanne-Marie Jacquet; Alix Collard; Dorothee Kieninger; Claudius U Meyer; Claire-Anne Siegrist; Fred Zepp

doi:10.1016/j.jpeds.2009.12.019

Booster vaccination after neonatal priming with acellular pertussis vaccine

J Pediatr. 2010 Apr;156(4):675-8. doi: 10.1016/j.jpeds.2009.12.019.

Authors

Markus Knuf¹, Heinz-Josef Schmitt, Jeanne-Marie Jacquet, Alix Collard, Dorothee Kieninger, Claudius U Meyer, Claire-Anne Siegrist, Fred Zepp

Affiliation

¹ Department of Pediatrics, Johannes Gutenberg-University, Mainz, Germany. [email protected]

PMID: 20303444
DOI: 10.1016/j.jpeds.2009.12.019

Abstract

After a birth dose of acellular pertussis (aP) and diphtheria (DT)aP-hepatitis B virus (HBV)-inactivated polio vaccine (IPV)/Haemophilus influenza type b (Hib) at 2, 4, and 6 months, a booster dose of DTaP-HBV-IPV/Hib at 12 to 23 months induced strong anti-pertussis booster responses. Thus, neonatal aP priming did not lead to immune tolerance to pertussis antigens. However, it elicited bystander interference on HBV, Hib, and diphtheria responses.

Trial registration: ClinicalTrials.gov NCT00289796.

Publication types

Comparative Study
Randomized Controlled Trial
Research Support, Non-U.S. Gov't

MeSH terms

Dose-Response Relationship, Drug
Follow-Up Studies
Humans
Immunization, Secondary / methods*
Infant
Infant, Newborn
Pertussis Vaccine / administration & dosage*
Prognosis
Vaccination / methods*
Vaccines, Acellular
Whooping Cough / prevention & control*

Substances

Pertussis Vaccine
Vaccines, Acellular

Associated data

ClinicalTrials.gov/NCT00289796